Fortis Therapeutics develops antibody-drug conjugates targeting CD46 proteins to selectively eliminate tumor cells while preserving healthy tissue. This precision approach enhances treatment efficacy and minimizes collateral damage, addressing the limitations of traditional cancer therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer treatments often lack specificity, damaging healthy cells alongside cancerous ones, leading to significant side effects and limiting treatment efficacy. This lack of precision necessitates higher dosages and more aggressive regimens, further compromising patient well-being.
Solution
Fortis Therapeutics is developing antibody-drug conjugates (ADCs) that selectively target CD46 proteins, which are highly expressed on tumor cells but less prevalent on healthy tissues. By precisely targeting CD46, Fortis's ADCs aim to deliver cytotoxic payloads directly to cancer cells, minimizing off-target effects and preserving healthy tissue. This targeted approach seeks to improve treatment outcomes by enhancing efficacy while reducing the debilitating side effects associated with conventional chemotherapy and radiation. The company's technology focuses on creating a more selective and tolerable cancer therapy.
Target Audience
The primary target audience includes cancer patients who could benefit from more targeted and less toxic treatment options, as well as oncologists seeking to improve patient outcomes and quality of life.
Features
- Antibody-drug conjugates (ADCs) designed for selective targeting of CD46 proteins.
- Precision delivery of cytotoxic payloads to tumor cells.
- Minimized off-target effects to preserve healthy tissue.
- Enhanced treatment efficacy compared to traditional therapies.
- Reduced side effects for improved patient tolerability.